Overview

  • Product nameAnti-PADI4 / PAD4 antibody
    See all PADI4 / PAD4 primary antibodies
  • Description
    Rabbit polyclonal to PADI4 / PAD4
  • Tested applicationsWB, IHC-Pmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Recombinant fragment containing a sequence corresponding to a region within amino acids 326-581 of Human PADI4/ PAD4 (AAH25718).

  • Positive control
    • HeLa and HepG2 whole cell lysates

Properties

Applications

Our Abpromise guarantee covers the use of ab96758 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/500 - 1/3000. Predicted molecular weight: 74 kDa.
IHC-P 1/100 - 1/500.

Target

  • FunctionCatalyzes the citrullination/deimination of arginine residues of proteins. Citrullinates histone H3 at 'Arg-8' and/or 'Arg-17' and histone H4 at 'Arg-3', which prevents their methylation by CARM1 and HRMT1L2/PRMT1 and represses transcription. Citrullinates EP300/P300 at 'Arg-2142', which favors its interaction with NCOA2/GRIP1.
  • Tissue specificityExpressed in eosinophils and neutrophils, not expressed in peripheral monocytes or lymphocytes.
  • Involvement in diseaseGenetic variations in PADI4 are a cause of susceptibility to rheumatoid arthritis (RA) [MIM:180300]. It is a systemic inflammatory disease with autoimmune features and a complex genetic component. It primarily affects the joints and is characterized by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Note=Could have an important role in the pathogenesis of rheumatoid arthritis by increasing citrullination of proteins in rheumatoid arthritis synovial tissues, leading, in a cytokine-rich milieu, to a break in tolerance to citrullinated peptides processed and presented in the appropriate HLA context.
  • Sequence similaritiesBelongs to the protein arginine deiminase family.
  • Cellular localizationCytoplasm. Nucleus. Cytoplasmic granule. Cytoplasmic granules of eosinophils and neutrophils.
  • Information by UniProt
  • Database links
  • Alternative names
    • EC 3.5.3.15 antibody
    • HL 60 PAD antibody
    • HL-60 PAD antibody
    • PAD 4 antibody
    • PAD antibody
    • PADI 4 antibody
    • PADI 5 antibody
    • PADI H protein antibody
    • Padi4 antibody
    • PADI4_HUMAN antibody
    • PADI5 antibody
    • PDI 4 antibody
    • PDI 5 antibody
    • PDI4 antibody
    • PDI5 antibody
    • Peptidyl arginine deiminase type IV antibody
    • Peptidyl arginine deiminase type V antibody
    • Peptidylarginine deiminase IV antibody
    • Protein arginine deiminase antibody
    • Protein arginine deiminase type 4 antibody
    • Protein arginine deiminase type IV antibody
    • Protein-arginine deiminase type IV antibody
    • Protein-arginine deiminase type-4 antibody
    see all

Anti-PADI4 / PAD4 antibody images

  • All lanes : Anti-PADI4 / PAD4 antibody (ab96758) at 1/1000 dilution

    Lane 1 : HeLa whole cell lysate
    Lane 2 : HepG2 whole cell lysate

    Lysates/proteins at 30 µg per lane.


    Predicted band size : 74 kDa
  • Immunohistochemical analysis of PADI4 / PAD4 in paraffin-embedded Cal27 xenograft, using ab96758 at 1/100 dilution.

References for Anti-PADI4 / PAD4 antibody (ab96758)

This product has been referenced in:
  • Kolodziej S  et al. PADI4 acts as a coactivator of Tal1 by counteracting repressive histone arginine methylation. Nat Commun 5:3995 (2014). ChIP, WB ; Human . Read more (PubMed: 24874575) »

See 1 Publication for this product

Product Wall

There are currently no Abreviews or Questions for ab96758.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"